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Abstract
Determining the factors that lead to successful enrollment of patients in cancer control clinical
trials is essential as cancer patients are often burdened with side effects such as pain, nausea, and
fatigue. One promising intervention for increasing enrollment in cancer control trials is the
National Cancer Institute’s Community Clinical Oncology Program (CCOP). In this article, we
examined CCOP staffing, polices, and procedures associated with enrollment in control trials.
Data were obtained from three sources: the online CCOP, MB-CCOP, and Research Base
Management System, CCOP Annual Progress Reports, and a survey of CCOP Administrators
conducted in 2011. We analyzed cancer control trial accrual in 2011 among 46 CCOPs using
multivariate regression. Three factors were significant predictors of accrual. First, having a team
of staff dedicated to enrolling patients in control and prevention trials, compared to having no
dedicated staff, was associated on average with an additional 30 patients enrolled in control trials
(p <0.05). Second, CCOPs that recognized physicians for enrolling a large number of patients
compared to CCOPs that did not recognize high enrolling physicians enrolled on average an
additional 25 patients in control trials (p <0.05). Lastly, the number of cancer control trials
available was also associated with enrollment (β = 5.50, p<0.00). Our results indicate that CCOPs
looking to increase enrollment in control trials should consider dedicating a team of staff to enroll
patients in these types of trials. In addition, CCOPs or other volunteer research systems looking to
increase physician participation should consider recognizing high enrolling physicians.
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Despite evidence that clinical trials play a critical role in developing innovative treatments
and in refining cancer prevention and control strategies, only 3–5% of adults with cancer in
the United States participate in clinical trials [1]. One promising intervention for increasing
participation in cancer clinical trials is the Community Clinical Oncology Program (CCOP).
The CCOP network is a joint venture between the National Cancer Institute (NCI)’s
Division of Cancer Prevention, which provides overall direction and funding, research
bases, which design clinical trials, and community-based networks of providers (CCOPs),
which assist with enrollment, data collection, and dissemination of study findings [2–8].
Although all three components of the network are critical to the success of the national
program, the goal of this analysis is to identify the CCOP staffing, polices, and procedures
associated with enrollment in NCI-sponsored cancer control trials. As defined by CCOP,
cancer control trials test the effectiveness of symptom management, rehabilitation, and
continuing care interventions to minimize cancer burden and improve quality of life [9].
Determining the factors that lead to successful enrollment of patients in cancer control trials
is important for clinical care [10]. Among patients with advanced cancer, the majority
experience moderate to severe pain, fatigue, anorexia, and/or nausea [11,12]. These side
effects may persist even after active treatment ends. Efforts to improve side effects have not
kept pace with efforts to develop innovative cancer treatments [13]. As the number of cancer
survivors continues to grow, addressing the burden of cancer related side effects will
continue to be important [13].
Understanding the factors that lead to successful enrollment of patients in control trials is
also important for CCOP administrators. The landscape of available clinical trials is
changing. In the past, CCOPs met a significant portion of NCI accrual expectations through
large-scale cancer prevention trials [2]. For example, CCOPs overall provided
approximately 30% of the enrollment in the Breast Cancer Prevention and the Selenium and
Vitamin E Cancer Prevention Trials [2]. As the number and scale of prevention trials
decrease, there is an increasing need to meet accrual expectations through enrollment in
cancer control clinical trials.
Prior research of cancer control trial accrual in the CCOP network has examined control and
prevention trial enrollment together [3,4,5,6]. Quantitative analyses have focused on fixed
organizational structural and environmental factors that contribute to enrollment [3,4].
CCOP administrators, however, are unable to modify these factors to increase enrollment in
clinical trials. There have also been a number of case studies of successful CCOPs [5,6].
These studies tend to focus on prevention enrollment. Although some of the strategies also
apply to control trials (e.g., dedicated research staff), others are not as relevant (e.g., mass
media campaigns) [5].
In this article, we examine modifiable CCOP staffing, operational polices, and procedures to
determine their effect on enrollment in cancer control trials. We believe our results are
relevant beyond CCOPs to other clinical research programs conducted within community
settings. Our findings are particularly applicable for volunteer research programs hoping to
encourage physician participation in clinical research.
2. Materials and Methods
Study Setting and Population
The study population is the NCI CCOP network. As of November 2012, 47 CCOPs and 17
Minority-based CCOPs (MB-CCOPs) operated in 35 states and Puerto Rico. MB-CCOPs
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primarily focus on enrolling minority patients into NCI-sponsored clinical trials. MB-
CCOPs also tend to be located primarily at academic medical centers or universities,
whereas university hospitals may be part of some CCOPs, they cannot be the lead
organization. Therefore, MB-CCOPs also tend to be located in more urban areas than
participating CCOPs, which focus on enrolling patients in a local or community setting. We
had to exclude MB-CCOPs from this analysis, as T-tests and Chi X2 tests demonstrated that
they are systematically different than the CCOPs. For example, CCOPs on average enrolled
over 108 patients to cancer control trials while MB-CCOPs only enrolled 37 patients. In
addition, the number of available cancer control trials was on average 21 trials for CCOPs,
but only 10 trials on average for MB-CCOPs. Both differences were statically significant.
Thus, we did not feel comfortable combining both CCOPs and MB-CCOPs in a single
analysis.
The specific sample for this study includes 46 CCOPs, as an additional CCOP joined the
program after the data was collected. In total, the CCOP network includes over 450 hospitals
and physician practices, with the average CCOP comprised of about 10 hospitals or practice
sites. CCOPs also include over 2,000 physicians, with the average CCOP composed of 48
physicians.
Study Design and Data Sources
The study used a cross-sectional design with the CCOP as the unit of analysis. We obtained
data from three sources. The online CCOP, MB-CCOP, and Research Base Management
System, maintained by NCI Division of Cancer Prevention, provided data on CCOPs’ 2011
menu of NCI-sponsored cancer control trials and CCOPs’ 2011 patient enrollment into those
trials. Second, the progress reports that CCOPs submit annually to NCI provided data on the
CCOP’s cancer patient volume. The progress reports covered the nine-month period from
June 2010 through February 2011. Finally, a survey of CCOP Administrators conducted in
the fall of 2011, provided data on the total number of CCOP staff (including CCOP-funded
and non-CCOP funded staff) in 2011, cancer control and prevention dedicated staff in 2011,
and whether the CCOP recognizes physicians for enrolling patients and/or expects
physicians to enroll a certain number of patients per year. The goal of the survey was to
learn more about how the CCOPs are organized and how they operate. The survey
specifically addressed CCOP organizational structure, sponsored educational trainings,
physician resources and support for screening, consenting, and enrolling patients, as well as
CCOP staffing procedures. The survey was designed and administrated with the support of
NCI Division of Cancer Prevention officials. Although the time periods covered by the three
data sources do not overlap perfectly, the CCOP features examined in this study exhibit only
small fluctuations from year to year.
Measures
The study’s outcome was patient enrollment (i.e., accrual) in NCI-sponsored cancer control
trials in 2011. We did not include accrual into cancer prevention trials. Given the goal of this
article was to determine CCOP staffing, organizational polices, and procedures that
influence cancer control trial enrollment, we selected two sets of factors that we felt CCOP
administrators could modify and would influence future planning and CCOP operations.
The first factor characterizes the CCOP’s staffing arrangement and included two measures:
(1) Number of CCOP research staff in 2011, defined as the number of non-physician
personnel supported by CCOP research grants and the number of staff who worked on NCI
CCOP trials who were not supported by CCOP funds (e.g., whose salaries were covered by
participating hospitals); and (2) Number of CCOP research staff dedicated to control and
prevention trials who focused on enrollment in NCI-sponsored cancer control and
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prevention trials in 2011. We were unable to distinguish cancer control dedicated staff from
those focused on prevention. Given the average enrollment in cancer prevention trials was
only nine patients and CCOPs enrolled on average 109 patients in cancer control trials,
however, it is likely that these staff focused a significant portion of their time on cancer
control enrollment. This measure was assessed as having no dedicated staff, one staff
member, or more than one staff member dedicated to cancer control and prevention trial
accrual. We decided to look at cancer control and dedicated staff this way, as we wanted to
compare having a small or large staff to having no dedicated staff. Including dedicated staff
as a continuous variable would only allow us to examine the effect of adding an additional
staff person on total enrollment.
The second factor characterizes the CCOP’s organizational policies and procedures. The
first two measures included: (1) Recognition of physicians for enrolling patients, and (2)
Expectation for physicians to enroll patients. Recognition of high enrolling physicians was
defined as whether the CCOP provided some form of recognition to physicians with high
levels of accrual to NCI-sponsored clinical trials (e.g., public acknowledgement, small
tokens of appreciation) in 2011, assessed as yes or no. Expectations for enrollment was
defined as whether the CCOP expected physicians to enroll a minimum number of patients
in any type of NCI-sponsored clinical trial, including formal and informal communications
in 2011. This measure was also assessed as yes or no. We included these CCOP policies,
which focus on the accruing physicians, in the analysis because although CCOP support
staff are instrumental in helping to recruit and consent patients, ultimately accrual to all
types of clinical trials is attributed to individual physicians. Thus, CCOP-affiliated
physicians may be more involved in cancer control trial enrollment than are physicians in
other settings, making these policies potentially relevant factors that influence patient
enrollment in cancer control trials. In addition, some physicians may be less likely to enroll
patients in cancer treatment trials compared to cancer control trials, as they may be more
likely to disagree with the specific protocol. For example, in an interview with a CCOP-
affiliated physician, the physician explained he was much more comfortable putting patients
on cancer control trials and tended to refer patients to these types of trials compared to
treatment trials. Therefore, implementing expectations for enrollment or recognizing high
enrolling physicians are modifiable CCOP organizational policies that may drive cancer
control trial enrollment.
The last CCOP organizational procedure is: (3) Number of open NCI Cancer Control trials
for which the CCOP had at least one patient enrolled in 2011. Given our measure for the
number of open cancer control trials included only trials with at least one patient enrolled,
we ran a series of sensitivity test to ensure it was robust to small variations in the total
number of open trials. The results from these tests are described below. Lastly, we also tried
to control for differences in CCOP size by including one additional measure: (1) Number of
newly diagnosed cancer patients seen in participating CCOP hospitals in 2009 (the most
recent year of data available for this measure for this study).
Statistical Analysis
We utilized ordinary least squares (OLS) multivariate regression models to analyze our
results. OLS allows us to explain the total enrollment in cancer control trials according to
the variables selected above by fitting a line through data in such a way that the sum of the
vertical lines from the data to the fitted line, squared, are minimized [14]. To use OLS
appropriately, several assumptions must be met. Two assumptions that warrant testing are
the assumption of homoskedasticity (i.e., constant variance for all observations) and the
assumption that the error term is normally distributed. Although neither of these
assumptions bias our parameter estimates, further adjustments to the model may be
necessary to ensure our significance tests are valid [15]. We tested for non-normality of the
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error term by running a skewness and kurtosis test for normal distribution, and for
homoskedasticity by running the White test for homoskedasticity. Our data was both non-
normal and heteroskedastic. We therefore, bootstrapped our data at 1,000 repetitions and
used the 95% bias-corrected confidence intervals to determine the significance and the
marginal effects for each included variable. All analyses were conducted in Stata 12
(StataCorp. 2009. Stata Statistical Software: Release 12. College Station, TX: StataCorp
LP).
3. Results
In 2011, CCOPs accrued an average of 109 patients in NCI-sponsored cancer control trials
(Table 1). Cancer control accrual ranged from 17 to 407 patients. On average, CCOPs had
approximately 21 open cancer control trials with at least one patient enrolled. The mean
number of newly diagnosed cancer patients per year was 5802. The mean number of total
research staff per CCOP was 19. The mean number of CCOP research staff dedicated to
enrolling patients in cancer control and prevention trials was 3.6. About 61% of CCOPs
recognized physicians for enrolling patients into clinical trials and about 35% had informal
or formal expectations communicated to physicians on the number of patients they should
enroll in trials each year.
Bootstrapped OLS results indicate that there were three significant predictors of cancer
control trial accrual (Table 2): (1) number of open cancer control trials (p<0.00), (2) having
more than one research staff member dedicated to enrolling patients in cancer control and
prevention trials (p<0.05), and (3) CCOP recognition of physicians for enrolling patients in
clinical trials (p<0.05). The bias-corrected marginal effects indicate that a one-trial increase
in the number of open cancer control trials can lead to on average an additional 5.5 patients
enrolled in cancer control trials. Having more than one staff member dedicated to cancer
control and prevention trial enrollment compared to having zero staff members dedicated to
cancer control and prevention trials is associated with on average an additional 30 patients
enrolled. Lastly, CCOPs that recognized physicians who enrolled a large number of patients
into clinical trials, compared to those that did not, can lead on average to an additional 25
patients enrolled in cancer control trials.
Sensitivity Tests
Due to data constraints, our measure of the number of open cancer control trials included
only those trials for which a CCOP had at least one patient enrolled. We ran a series of
sensitivity tests to assess the robustness of our results to different assumptions regarding the
number of additional cancer control trials a CCOP had open that had no enrollment. In the
first three scenarios, we assumed that all CCOPs had the same percentage of cancer control
trials with no accrual. In these models, we increased the number of open cancer control trials
for all CCOPs by 10%, 20%, 30% respectively. In the fourth scenario, we assumed that
CCOPs varied randomly in the percentage of open cancer control trials with no accrual. In
this model we randomly increased the number of open cancer control trials across CCOPs
from 0% to 20%. In the final scenario, we assumed that higher performing CCOPs were
more “efficient” than lower performing CCOPs in terms of only opening trials that had a
strong probability of accrual or in terms of quickly closing trials that exhibited no accrual.
For this model, we increased the number of open cancer control trials by 0% for CCOPs in
the highest quintile of cancer control accrual, 5% for CCOPs in the second highest quintile,
10% in the third highest quintile, and so on. In all five sensitivity tests, we obtained nearly
identical results to those reported above.
Jacobs et al. Page 5














Our goal was to identify the CCOP staffing, organizational polices, and procedures
associated with patient enrollment in cancer control clinical trials. We found three
significant factors. First, having dedicated cancer control and prevention staff was a
significant determinant of enrollment. Enrolling patients in cancer control trials was not
dependent on the size of the total CCOP staff, but rather was dependent on the size of the
dedicated staff of the CCOP. For example, the total number of CCOP staff was not a
significant predictor of cancer control trial enrollment. In addition, CCOPs with only one
staff member dedicated to cancer control and prevention trials did not significantly enroll
more patients in cancer control trials than CCOPs who had no dedicated staff members.
CCOPs with a team of staff dedicated to cancer control and prevention, however, enrolled
on average an additional 30 patients compared to CCOPs with no dedicated staff.
Enrolling patients in cancer control trials requires a team of staff dedicated to identifying,
recruiting, enrolling, and administrating the trials. Our results support the notion that the
degree of work required to accrue to cancer control trials is larger than one person can
manage. For example, cancer control studies tend to have more patient reported forms to
complete, which can take more time and coordination among staff. Cancer control trials are
also generally shorter in duration than treatment trials, but the work involved while a patient
is on a study may be more time consuming, which would take a single cancer control staff
person away from recruitment efforts. In addition, having only one or no dedicated cancer
control staff is likely reflective of the importance a CCOP places on accruing to cancer
control trials. Although our analysis was not able to take into account the varying knowledge
and/or skill of the cancer control dedicated staff, our results are indicative that successful
cancer control accrual is dependent on having a team of staff in place.
Although physicians may play less of a predominant role in cancer control trial accrual than
they do in treatment trial accrual, given their primary focus of treating cancer, recognizing
physicians for enrolling patients can make a significant impact on CCOP cancer control trial
accrual. CCOPs that recognized high enrolling physicians compared to those that did not
recognize physicians, on average accrued an additional 25 patients to cancer control trials.
One reason that providing recognition for top physician accruers may be a significant
predictor of cancer control enrollment is that although physicians are never paid directly for
their recruitment efforts, physicians are competitive by nature and recognition in front of
their peers is an effective motivator to approach and enroll eligible patients. For example, in
interviews with one CCOP in the Midwestern United States, the research staff explained that
they hold an annual competition among physicians to see who can enroll the most patients.
The CCOP awards an actual crown at the annual Christmas party to the physician with the
highest number of patients enrolled in clinical trials. Clinical research staff at this CCOP
noted that this competition is an effective motivator for their physicians. Although most
physicians will not win or come close to winning, the competition is a motivator for
recruitment, as they do not want to come in last place. In addition to motivating physicians
to enroll patients, the competition also keeps enrollment and clinical trials top of mind.
Physicians may receive both informal and formal recognition for their accrual efforts. For
example, when a physician enrolls a patient in a cancer control trial, they may be
immediately recognized and appreciated informally by cancer control support staff. These
interactions between dedicated cancer control staff and physicians strengthen the overall
recruitment efforts of the team. The majority of CCOPs also provide some form of formal
recognition for physicians that enroll a large number of patients. There are two main ways
CCOPs recognize physicians for their accrual efforts. The first is providing some sort of
public recognition. Most of the CCOPs that recognized doctors publically acknowledged top
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accruers for example, in monthly newsletters, at research or annual meetings, or on public
websites. Some of the CCOPs that recognized accrual efforts provided small tokens or gifts
to top enrollers such as a coffee gift card, gift basket, or a plaque/trophy. Many CCOPs that
recognized physicians did a combination of both public acknowledgement and a small gift
or trophy. Therefore, CCOPs or any other clinical trial programs in the community setting
that want to increase the enrollment of patients may want to consider adding some sort of
small reward, competition, or public acknowledgment of top enrolling physicians. Other
volunteer research systems may also want to consider recognizing physicians as a way to
increase physician involvement and motivation, as it can be a simple, effective, and easy
system to implement.
Lastly, the number of open cancer control trials with at least one patient enrolled was also a
significant predictor of enrollment of CCOPs. It is not surprising that having access to a
large menu of available cancer control trials can lead to more patients enrolled. Although the
number of open trials is significant, an increase of one available cancer control trial was
only associated on average with an additional 5.5 patients enrolled overall. Five additional
patients is far less than the other two significant factors, recognition and cancer control
dedicated staff, where each contributed to over 25 additional patients enrolled.
A number of factors included in the analysis were not significant predictors of cancer
control accrual. First, the volume of newly diagnosed patients at the CCOP was not a
significant predictor of cancer control enrollment. Originally, we thought having more
newly diagnosed patients would give CCOPs more chances to enroll patients in cancer
control trials. This was not the case, however. This factor may not have been significant
because it is not a true reflection of the number of newly diagnosed patients that the CCOP
participating physicians actually treat and are eligible for a clinical trial. Our estimate of the
number of newly diagnosed patients comes from the CCOP Annual Progress Reports, which
generally use information from the hospital-based registry and thus do not take into account
the actual number of patients referred or accessible to a CCOP participating physician. Thus
it may be insignificant due to a measurement problem. In addition, the number of newly
diagnosed patients may be more applicable in other studies that examine the predictors of
treatment trial accrual compared to our analysis where we focused exclusively on cancer
control accrual.
Having an informal or formal expectation for physicians to enroll a certain number of
patients was also not a significant predictor of cancer control accrual. This may be because
the majority of CCOPs do not set any expectations for enrollment. In addition, among
CCOPs that did have some sort of formal or informal expectation, the requirement was low,
generally just several patients per year. Given that the requirements are low and not specific
to cancer control trials, the majority of physicians may be fulfilling any requirements by
enrolling patients in treatment trials.
Limitations
As with any analysis, there are a number of limitations. First, we only have a sample size of
46 CCOPs. Although OLS regression can work with small samples, ideally the sample size
should be at least about 10 times the number of explanatory variables, which in our case is at
least a sample size of 60 CCOPs [14]. Although 60 CCOPs would be ideal, there are a
limited number in the program. In addition, if we had excluded potentially relevant variables
in the analysis due to sample size, our estimates would be biased. For example, total
combined staff is significantly positively correlated both with the outcome, cancer control
enrollment, and the independent variable, number of available cancer control trials. If we
had left out total combined staff our coefficients estimates would be biased upwards and
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thus not reflect an accurate portrayal of the factors that influence cancer control enrollment
[15].
In addition, this analysis is cross-sectional and only represents a snapshot of the cancer
control enrollment and the number of available cancer control trials at a given point in time.
This study is unique and significant, however, as much of the data comes from the CCOP
Administrator Survey, which contains information never before collected and analyzed
about the CCOP program.
Overall, this analysis highlights the importance of conducting clinical trials in the
community setting. Although cancer treatment trials are imperative for the development of
innovative cancer therapies, this paper emphasizes trials to reduce suffering and increase the
quality of life for current cancer patients. Our results are meaningful in that they provide
tangible strategies that are implementable for practice administrators to increase physician
participation in volunteer research programs and extend the oncologist’s role beyond the
role of only a treatment provider, and into a role that includes caring for their cancer patient
across the entire care continuum.
5. Conclusion
Although cancer clinical trials are important in the development of new treatments and
innovative cancer control and prevention strategies, only 3–5% of American adults with
cancer participate [1]. One strategy aimed at increasing enrollment, the community-based
CCOP network, has been successful in increasing enrollment specifically in cancer symptom
management trials [2]. In this analysis we examined the impact of modifiable CCOP
staffing, organizational polices, and procedures on the enrollment in NCI-sponsored cancer
control related trials. The two largest determinants are (1) having a staff dedicated to cancer
control and prevention trial enrollment and (2) recognizing high enrolling physicians for
their accrual efforts, both of which on average increased enrollment in cancer control trials
by over 25 patients each. CCOPs wanting to increase enrollment specifically in cancer
control trials may want to consider dedicating a team of staff to enroll patients in cancer
control trials as well as recognizing high enrolling physicians. These results are applicable
beyond CCOPs and may be useful for other volunteer research systems looking to increase
physician motivation and involvement.
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Table 1
Summary Statistics of CCOP Enrollment in NCI-Sponsored Cancer Control Trials, 2011




 Patient Enrollment in NCI- Sponsored Cancer Control Trials 108.67 (91.36) (17,407)
Independent Variables
 Number of Open Cancer Control Trials 20.83 (9.92) (5,45)
 Number of Newly Diagnosed Patients 5801.80 (4923.84) (238, 28746)
 Total Number of CCOP Staff 19.14 (13.36) (2,79.7)
 Total Number of Staff Dedicated to Enrolling Patients in Cancer Prevention and
Control Trials
3.63 (5.66) (0,26)
  CCOPs with No Staff Dedicated to Prevention and Control Trials 23.91%
  CCOPs with One Staff Member Dedicated to Prevention and Control Trials 19.57%
  CCOPs with More than One Staff Member Dedicated to Prevention and Control
Trials
56.52%
 Recognition of Physicians for Enrolling Patients into Clinical Trials
  Yes 60.87%
  No 39.13%
 Expectations for Physicians to Enroll Patients into Clinical Trials
  Yes 34.78%
  No 65.22%
*
Standard deviations in parenthesis
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Table 2
Marginal Effects from Bootstrapped OLS Regression Model
Marginal Effects+ n=46
Adjusted R2 = 0.7426
Bias-Corrected 95% Confidence
Interval
Number of Open Cancer Control Trials 5.49* (1.11) 3.51 to 7.69
Number of Newly Diagnosed Patients 0.004 (0.002) −.002 to .008
Total Number of Staff .848 (.74) −.360 to 2.64
Staff Dedicated to Enrolling Patients in Control and Prevention Trials
 One Staff Member Dedicated to Prevention and Control Trials −22.16 (20.64) −70.87 to 14.09
 More Than One Staff Member Dedicated to Prevention and Control Trials 29.98* (15.22) .816 to 60.31
Recognition of Physicians for Enrolling Patients in Clinical Trials
 Provides Recognition 25.35* (11.65) 3.43 to 47.72
Expectations for Physicians to Enroll Patients in Clinical Trials
 Has Expectation 3.47 (17.76) −34.23 to 34.39
Constant −71.65
+
Bootstrapped standard errors in parentheses
*
Indicates significant at the .05 level
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